Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD1 | P21728 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7867642 | 1.00 | KMT2A (0.41) | KMT2AMEN1RAB9AALDH1A1TSHR | |
| SCHEMBL18484463 | 1.00 | KMT2A (0.41) | KMT2AMEN1RAB9AALDH1A1TSHR | |
| SCHEMBL25730521 | 0.81 | SLC6A2 (0.47) | KMT2AMEN1RAB9AALDH1A1TSHR | |
| SCHEMBL14805869 | 0.81 | ALDH1A1 (0.37) | KMT2AMEN1RAB9AALDH1A1TSHR | |
| SCHEMBL8168773 | 0.81 | FUCA1 (0.50) | ALDH1A1SIGMAR1 | |
| SCHEMBL5184184 | 0.78 | DPP7 (0.41) | KMT2AMEN1RAB9AALDH1A1 | |
| SCHEMBL4780977 | 0.78 | ALOX15 (0.38) | SLC6A2SLC6A4DRD2 | |
| SCHEMBL12627343 | 0.76 | SLC6A2 (0.41) | KMT2AMEN1ALDH1A1TSHRSLC6A2 | |
| SCHEMBL4776044 | 0.75 | RORC (0.41) | SLC6A2SLC6A4 | |
| SCHEMBL4778958 | 0.75 | ADRA1D (0.48) | ALDH1A1SLC6A2SLC6A4SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | KMT2A 2823/4885MEN1 4082/4885RAB9A 3071/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | KMT2A 2823/4885MEN1 4082/4885RAB9A 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.